AI assistant
Sending…
Editas Medicine, Inc. — Director's Dealing 2018
Jan 25, 2018
33260_dirs_2018-01-25_bb22c6af-99f9-4d60-a58b-7df412c87907.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2018-01-23
Reporting Person: Bosley Katrine (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-01-23 | Common Stock | S | 3338 | $35.28 | Disposed | 1364431 | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017.
F2: This transaction was executed in multiple trades at prices ranging from $35.21 to $35.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
More from Editas Medicine, Inc.
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 5
Annual Report
2026
Apr 28
Regulatory Filings
2026
Apr 7
Regulatory Filings
2026
Mar 27